This is our largest site with 70+ employees and a continuous production of 100+ PXB-mice per week. In addition to in vivo study services for NAFLD/NASH, viral hepatitis, gene-based therapeutics, DMPK/toxicology, and custom transplantations, we also offer HBV study services at this location.
This office is responsible for all non-Japanese clients. We complete project management, marketing, and sales from this office.
This is a production facility for PXB-mice and PXB-cells.
The Chimeric Mouse with a Humanized Liver (CMHL) Consortium was started by PhoenixBio to work with pharmaceutical industry and academic leaders to enhance applications and translational research using the PXB-mouse model. As of 2021, a total of 11 institutions, including eight pharmaceutical companies, are participating in the research.
Company Name | PhoenixBio Co., Ltd. |
Established | March 4th, 2002 |
President and CEO | Takashi Shimada |
Fiscal term | March |
Capital | 2,453 million yen (Mar.2023) |
URL | https://phoenixbio.co.jp/ |
Headquarters | 3-4-1 Kagamiyama, Higashi-Hiroshima City 739-0046 Japan |
PhoenixBio USA Corporation | 1120 Avenue of the Americas, Suite 1513, New York NY, 10036 USA TEL +1-212-379-6411 FAX +1-212-379-6422 |
KMT Hepatech Inc. |
2011-94 Street NW, Edmonton, Alberta, Canada, T6N1H1 |
CMHL Consortium LLC |
Delaware, USA |
At PhoenixBio, our team strives to improve the global population’s quality of life and health through the application of our chimeric mouse model with a humanized liver. Our drive to improve the population’s health is central to the work we do to advance preclinical research and therapeutic development.
Kenji Kuramoto: | Chairman |
Takashi Shimada: | President & CEO |
Yasuhiro Tamura: | Executive Director of Administration |
Chise Tateno-Mukaidani, Ph.D.: | Executive Director of Research and Development |
Yoshinori Fujii: | External Director |
Motoyasu Ueno: | Full-time Auditor & Supervisory Board Member |
Masatsugu Ueda, Ph.D.: | Auditor & Supervisory Board Member |
Hiromi Okano: | External Auditor & Supervisory Board Member |
Yoshio Morikawa: | President & CEO, PhoenixBio USA Corporation |
Masakazu Kakuni, D.V.M., Ph.D.: | President, KMT Hepatech Inc. |
Contact us to find out how the PhoenixBio team could help your drug discovery and development projects today.